Biologics, antibodies, biosimilar and therapeutic proteins application:
Therapeutic proteins have made a significant portion of the biological drugs manufactured worldwide since the early 1980s. Most recent biological drugs have been produced using robust animal cell lines, including anchorage-dependent cell lines or those adapted for suspension growth. The Chinese Hamster Ovary (CHO) cell line is a prime example of commonly used cells in this process, indicating advancements in cell culture technologies.
The most popular technology for producing biologics in the US involves fed-batch and perfusion-based continuous or semi-continuous cultures. Before being scaled up to greater working volumes, methods in this sector are typically fine-tuned to culture cells to exceptionally high densities using complex medium and several nutrient feeds. Consistency issues with cell culture performance frequently develop during process scale-up, mostly as a result of differences in bioreactor geometry. These variations may result in early batch failures and possible product quality profile compromises.
OmniBRX Biotechnologies’ bioreactor systems are expertly designed to address prevalent bioprocessing challenges, including the implementation of state-of-the-art perfusion systems. Our CellBRX and PerfBRX® technologies are linearly scalable for adherent and suspension cell cultures spanning from 0.1 L to 5000 and ensure efficient bioprocessing. L addresses scale-up issues with precision and innovation.
Biologic Production Systems are the lifeblood of the pharmaceutical industry, underpinning the manufacturing of crucial Therapeutic Proteins. These are essential for assuring biologics’ reliable and effective manufacturing, which is the basis of contemporary medicine. Therapeutic proteins, like monoclonal antibodies and growth factors, are engineered using these sophisticated systems to combat a wide range of diseases, from cancer to autoimmune disorders.
The significance of biological production systems resides in their capacity to cultivate living cells in bioreactors to generate these therapeutic proteins industrially. This process demands precision and reliability, as even slight variations can affect the safety and efficacy of the final product. In today’s healthcare landscape, the development and optimization of Biologic Production Systems are paramount. They hold the key to enhanced efficiency, reduced production costs, and broader accessibility to crucial therapies, ultimately improving patient outcomes.
We are continually developing highly advanced bioprocessing technology to fulfill your unique demands. Innovative cell separation technologies are included in our PerfBRx® bioreactor systems to enable high cell-density continuous cultures, which are perfect for extensive therapeutic protein applications.
For consistent and cost-effective production of biologics using continuous perfusion-based suspension cell culture techniques, select PerfBRx® bioreactors. To discover more about PerfBRx® bioreactors, read more.
We advise adopting the DBR Technology-based CellBRx Bioreactor Systems for scalable and effective biologics production in adherent cell culture applications. Do not hesitate to contact us if you have any questions concerning CellBRx bioreactors, read more.